Patient Insights on Acne Hyperpigmentation, Trifarotene, and Skincare: 6-Month, LEAP Phase 4 Qualitative Exit Interview Findings
All trifarotene-treated patients reported improvements in AIH and that their treatment expectations were met. Findings support that trifarotene plus a skincare regimen provides greater benefit in the improvement of AIH than its VC. However, VC plus a skincare regimen also appeared to improve patients' perceptions of their AIH.
Authors
- Rajeev Chavda (ORCID: https://orcid.org/0000-0002-1959-1563)
- Jorge Puelles (ORCID: https://orcid.org/0000-0003-3493-1252)
- Jean Philippe York
- Natalie Taylor
- Kevin M. Chan
- Carla Dias-Barbosa (ORCID: https://orcid.org/0000-0003-4701-8825)
Institutions
- Galderma (United States) (US)
- Thermo Fisher Scientific (United Kingdom) (GB)
- Thermo Fisher Scientific (United States) (US)
- Galderma (Switzerland) (CH)
- Thermo Fisher Scientific (Israel) (IL)
Publication Details
- Journal
- Patient
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1007/s40271-025-00789-9
- Primary Topic
- Acne and Rosacea Treatments and Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Galderma